Your Partner for Dermatology Clinical Trial Management

Patient Recruitment

Recruitment in dermatology clinical studies is uniquely complex—especially for conditions with a strong cosmetic impact or biologics already available on the market. At RDI, we understand these barriers.

We leverage a pre-screened patient database of 19,000+ individuals who are motivated by unresolved symptoms, treatment fatigue, or wanting to advance research. We use targeted digital outreach to meet enrollment goals efficiently, with a nearly 37% diversity rate that aligns with FDA expectations for inclusive research.

Dr. Michelle Chambers, RDI’s resident dermatologist and principal investigator, brings decades of research experience and an extensive referral base to every study we conduct.

Patient Management

Our patient retention strategy begins the moment a participant walks through our doors—and it’s why we maintain a 97% retention rate across all studies. 

In dermatology, where visual symptoms can be psychologically and socially distressing, patients need clinical support, but also an environment where they feel seen and cared for. We offer free transportation, comfortable exam spaces, and personalized visiting scheduling. We make it a point to deliver prompt follow-ups and patient education while providing care in a warm, stress-free environment.

Many of our dermatology participants continue to take part in multiple studies with us, a testament to the level of care and communication they receive in the research process.

Data Collection

Photographic documentation is critical in dermatology clinical trials. Our team follows standardized imaging protocols for consistent lighting, distance, and exposure across visits. 

Clinical data is entered into our EDC platform the same day it’s collected. Sponsors benefit from real-time performance insights, and remote teams can monitor trial progress without delay.

Regulatory Compliance

Dermatology research increasingly involves complex immunomodulatory treatments such as JAK inhibitors and monoclonal antibodies. These investigational agents require careful coordination and protocol fidelity.

Our team follows ICH-GCP and FDA regulatory requirements, providing comprehensive support from study start-up through close-out. We work collaboratively with sponsors and monitors to adjust to evolving trial needs and timelines, while remaining vigilant about the unique safety profiles of emerging dermatologic therapies. 

This proactive, detail-oriented approach ensures compliance, data integrity, and participant safety throughout the duration of every study.